Protection of mRNA vaccines against hospitalized COVID-19 in adults over the first year following authorization in the United States.

ABSTRACT:

Background

COVID-19 mRNA vaccines were authorized in the United States in December 2020. Although vaccine effectiveness (VE) against mild infection declines markedly after several months, limited understanding exists on the long-term durability of protection against COVID-19-associated hospitalization.

Methods

Case control analysis of adults (≥18 years) hospitalized at 21 hospitals in 18 states March 11 - December 15, 2021, including COVID-19 case patients and RT-PCR-negative controls. We included adults who were unvaccinated or vaccinated with two doses of a mRNA vaccine before the date of illness onset. VE over time was assessed using logistic regression comparing odds of vaccination in cases versus controls, adjusting for confounders. Models included dichotomous time (<18

SUBMITTER: Tenforde MW 

PROVIDER: S-EPMC9129194 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature